Broxyquinoline, formerly known as Dibromoxyquinoline and NSC-1810, is a tetrahydrofolate dehydrogenase inhibitor used to treat vaginitis. Broxyquinoline induces VEGF transcription and shows angiogenic effects, stabilizes HIF-1α, and shows antiprotozoal and antifungal effects in vivo. References: Swain R, Bapna JS. Impairment of exercise tolerance due to broxyquinoline-brobenzoxaldine combination. Hum Toxicol. 1986 Jan;5(1):63-4. PubMed PMID: 3081430.

纯度：≥98%

CAS：521-74-4